Amyotrophic lateral sclerosis (ALS)

Brain inflammation
#Amyotrophic lateral sclerosis (ALS) #Axoltis Pharma #Blood brain barrier #Clinical trials #Neuroscience #Regulatory

Drug candidate for ALS patients authorised for Phase II trial

Axoltis Pharma has received authorisation from ANSM, the French agency for the safety of health products, to launch the SEALS study for Amyotrophic Lateral Sclerosis (ALS).   This Phase II clinical trial of drug candidate NX210c in patients with ALS is the first to target the integrity of the blood brain… Read More

#News #Regulatory

Biochemists working in the lab
#Amyotrophic lateral sclerosis (ALS) #Collaboration #Motor neurone disease #Oligonucleotides #PrecisionLife

R&D partnership to jointly develop new ALS drugs

PrecisionLife and the Nucleic Acid Therapy Accelerator (NATA) have announced a collaboration to co-develop novel oligonucleotide therapies for sporadic motor neurone disease/ALS. The collaboration combines NATA’s expertise in NAT design and optimisation with PrecisionLife’s understanding of complex disease biology and the mechanisms, drug targets and treatments… Read More

#News

#Alzheimer's #Amyotrophic lateral sclerosis (ALS) #Autism #Neurodegenerative disorders #Neuroscience #Parkinson's

New DDW Highlights podcast: 18 March 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Following the recent AD/PD 2024 conference, which took place on 5-9 March in Lisbon,… Read More

#News

#Alzheimer's #Amyotrophic lateral sclerosis (ALS) #Autism #Neurodegenerative disorders #Neuroscience #Parkinson's

This week in drug discovery (11-15 March) 

News round-up for 11-15 March by DDW Digital Content Editor Diana Spencer. Following the recent AD/PD 2024 conference, which took place on 5-9 March in Lisbon, Portugal, there have been a number of key announcements regarding investigational therapies for neurological disorders, particularly Alzheimer’s disease and Parkinson’s disease. Read More

#News

#Amyotrophic lateral sclerosis (ALS) #Clinical trials #Neuroscience #NeuroSense

NeuroSense reports positive results from its ALS trial 

NeuroSense Therapeutics has reported additional positive data from its six-month double-blind Phase IIb PARADIGM trial of its lead drug candidate PrimeC for the treatment of amyotrophic lateral sclerosis (ALS).   The PARADIGM trial’s secondary clinical efficacy outcome measure endpoints included Quality of Life and Survival. Consistent with the… Read More

#News